Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
World J Gastroenterol ; 14(1): 125-8, 2008 Jan 07.
Artículo en Inglés | MEDLINE | ID: mdl-18176974

RESUMEN

Bouveret's syndrome, defined as gastric outlet obstruction due to a large gallstone, is still one of the most dramatic biliary gallstone complications. Although new radiological and endoscopic techniques have made pre-surgical diagnosis possible in most cases and the death rate has dropped dramatically, "one-stage surgery" (biliary surgery carried out at the same time as the removal of the gut obstruction) should be still considered as the gold standard for the treatment of gallstone ileus.In this case, partial gastric outlet obstruction resulted in an atypical and insidious clinical presentation that allowed us to perform the conventional one-stage laparatomic procedure that completely solved the problem, thus avoiding any further complications.


Asunto(s)
Fístula Biliar/complicaciones , Cálculos Biliares/complicaciones , Fístula Gástrica/complicaciones , Obstrucción de la Salida Gástrica/etiología , Anciano , Fístula Biliar/cirugía , Femenino , Cálculos Biliares/cirugía , Fístula Gástrica/cirugía , Obstrucción de la Salida Gástrica/clasificación , Obstrucción de la Salida Gástrica/cirugía , Humanos
2.
Acta Biomed ; 77(3): 157-62, 2006 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-17312986

RESUMEN

BACKGROUND AND AIM: Constipation is one of the most common disorders in Western countries and it is known that dietary factors such as a low fiber diet and low caloric intake are associated with this condition. Weight loss can disrupt the intestinal ecosystem resulting in intestinal dysbiosis that worsens constipation. The aim of this study was to evaluate the effects of treatment with symbiotic zir fos (Bifidobacterium longum W11 + FOS Actilight) on chronic constipation in patients undergoing a weight loss diet. METHODS: Our evaluation included the recording of age, gender, weight, height, BMI, physical activity, constipation, diet, therapy compliance and laxative supplies. A hypocaloric diet (1,200/1,400 cal.) was prescribed to all patients, and they were submitted to a physical activity program and received 1 bag of symbiotic zir fos per day for the entire duration of the study. Patients' follow-up was available for up to 60 days. RESULTS: Two hundred and ninety seven patients (79.4% women and 18.2% men, mean age 32.2) were included in the study. The mean baseline BMI was 33.4 +/- 5.6 (range 22.8-56.3 Kg). The improvement of constipation turned out to be associated to age (p < 0.01). Patients with a mean age of 35 +/- 12 showed an improvement of constipation. BMI values were not significantly different among the groups of patients with improved, worsened or unchanged constipation. No significative difference was observed among groups due to physical activity. At the follow-up, after 20 days from the beginning of the study, patients that assumed at least 17/20 of the zir fos bags showed a greater improvement of constipation (p < 0.01) than the remaining patients who assumed less than 17/20 of the zir fos bags or that didn't assumed any at all. Patients that assumed laxatives (at least once a week) showedn to be more frequently associated with a worsening of constipation (p < 0.001). Diet compliance does not seem to influence the course of constipation. CONCLUSION: Our data demonstrate the utility of symbiotics in improving constipation during hypocaloric diet in the treatment of obesity.


Asunto(s)
Estreñimiento/terapia , Probióticos/uso terapéutico , Administración Oral , Adolescente , Adulto , Anciano , Antropometría , Catárticos/uso terapéutico , Niño , Estreñimiento/complicaciones , Defecación , Dieta , Dieta Reductora/efectos adversos , Ingestión de Energía , Femenino , Frutas , Humanos , Intestinos/microbiología , Masculino , Persona de Mediana Edad , Actividad Motora , Obesidad/complicaciones , Obesidad/dietoterapia , Obesidad/fisiopatología , Probióticos/administración & dosificación , Probióticos/efectos adversos , Resultado del Tratamiento , Verduras
3.
Hepatogastroenterology ; 52(61): 285-8, 2005.
Artículo en Inglés | MEDLINE | ID: mdl-15783051

RESUMEN

BACKGROUND/AIMS: To evaluate the utility of 2 biopsies of antrum and gastric body on routine endoscopy for the assessment of type III intestinal metaplasia (IM-3) and Helicobacter pylori (Hp), 1750 patients (pts) (895 males; 855 females) were considered from June'98 to June'00. METHODOLOGY: Specimens were graded 0 to 3 for atrophy, IM-3 and Hp. 610 pts treated previously with antibiotics or not eligible for biopsy were excluded from initial 2360 pts. RESULTS: IM-3 was found in 118 pts (6.7%), 100 pts (5.7%) only in the antrum. 10 of 355 pts (2.8%) with normal endoscopy and 47 of 702 (6.6%) with non-erosive endoscopic gastritis resulted IM-3 positive in the antrum. 709 pts (40.5%) were positive for Hp in antrum and/or corpus. The presence of Hp and IM-3 in the antrum was not correlated (p=0.99; Spearman test). A positive correlation (p=0.000) between duodenal ulcer and Hp was found when antral Hp positivity was taken into account. The gastric carcinoma risk index (GCRI) was found in 358 pts (20.4%); in this group 131 pts (36.6%) were Hp positive, 81 pts (22.65%) had IM-3 only in the antrum, 184 pts (51.4%) had atrophy. CONCLUSIONS: The incidence of IM-3 is low (6.7%) in routine endoscopy. Normal endoscopy doesn't exclude the presence of IM-3. Biopsy is necessary to discover IM-3 in the antrum in 5.3% of pts with normal or aspecific endoscopic gastritis. Application of the GCRI might be useful for identifying a group of patients carrying a higher risk for gastric carcinoma.


Asunto(s)
Gastritis Atrófica/patología , Infecciones por Helicobacter/patología , Helicobacter pylori , Intestinos/patología , Neoplasias Gástricas/etiología , Estómago/patología , Adulto , Anciano , Femenino , Estudios de Seguimiento , Gastritis Atrófica/complicaciones , Gastritis Atrófica/epidemiología , Infecciones por Helicobacter/complicaciones , Infecciones por Helicobacter/epidemiología , Humanos , Italia/epidemiología , Masculino , Metaplasia/complicaciones , Metaplasia/epidemiología , Metaplasia/patología , Persona de Mediana Edad , Prevalencia , Estudios Prospectivos , Medición de Riesgo
4.
Hepatogastroenterology ; 51(55): 176-80, 2004.
Artículo en Inglés | MEDLINE | ID: mdl-15011858

RESUMEN

BACKGROUND/AIMS: Duodenal gastric metaplasia seems to be linked to infection by Helicobacter pylori, to the extent of acid secretion and to bulbitis. An investigation was made of the relationship between bulbitis and duodenal gastric metaplasia, or whether bulbitis can arise along with duodenal gastric metaplasia after Helicobacter pylori eradication in an average of six years. METHODOLOGY: We compared 22 patients with duodenal ulcers [male/female 16/6; (mean age+/-SD) 55+/-12 years] Helicobacter pylori-negative after eradication, with 23 Helicobacter pylori-positive patients free from active duodenal ulcers [male/female 17/6; (mean age+/-SD) 59+/-12 years]. RESULTS: The bulbitis score was found to be lower in the Helicobacter pylori-negative than in the Helicobacter pylori-positive group (p=0.02). The duodenal gastric metaplasia score in the Helicobacter pylori-negative was higher than in the Helicobacter pylori-positive group (p=0.001). We failed to find any relationship between the presence of bulbitis and duodenal gastric metaplasia. We found a non-significant inverse correlation between the presence of duodenal gastric metaplasia and chronic body gastritis (p=0.07). CONCLUSIONS: Bulbitis and duodenal gastric metaplasia may depend on different causal factors not related to Helicobacter pylori infection. The extension of duodenal gastric metaplasia with time following recovery from peptic ulcer disease may represent a mucosal protection factor against acid.


Asunto(s)
Duodenitis/microbiología , Duodenitis/patología , Duodeno/patología , Mucosa Gástrica/patología , Infecciones por Helicobacter/patología , Helicobacter pylori , Anciano , Enfermedad Crónica , Células Epiteliales/patología , Femenino , Mucosa Gástrica/microbiología , Gastritis/microbiología , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos
5.
J Eval Clin Pract ; 15(1): 41-5, 2009 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-19239580

RESUMEN

RATIONALE, AIMS AND OBJECTIVES: Appropriate indications for colonoscopy (C) are essential for a rational use of resources. The aim of this study is to evaluate the appropriateness of indication for C according to the American Society for Gastrointestinal Endoscopy (ASGE) guidelines and to evaluate whether appropriate use was correlated with the diagnostic yield of C. METHODS: We analysed 677 consecutive C performed over an 11-month period in a digestive endoscopy unit with an open access system. RESULTS: The rate of 'generally indicated' C was 77% and 'generally not indicated' C was 18%. The rate of indication not listed in the ASGE guidelines was 5%. The percentage of generally not indicated C requested by gastroenterologists for outpatients was lower than that requested by primary care surgeons or doctors (9.5%, 29%, 25.3%, respectively). In 38 (7.3%) and in 111 (21.3%) of 520 patients with appropriate C, cancer and polyps larger than 5 mm were found, respectively. Twenty polyps greater than 5 mm were detected in 15 cases (12%) of 122 inappropriate C, with only one case of intramucosal carcinoma; four (12%) polyps measuring over 5 mm were found in C not listed in ASGE guidelines. No advanced stage cancer was detected in the inappropriate group and in C not listed in ASGE guidelines. CONCLUSIONS: Our results showed the high rate of inappropriate procedures, according to ASGE guidelines, requested by surgeons, internists and primary care doctors for both outpatients and inpatients. The proportion of not indicated endoscopic procedures requested by gastroenterologists must be reduced through more carefully application of ASGE guidelines. Endoscopic findings were more stringent in appropriate C.


Asunto(s)
Colonoscopía/normas , Guías como Asunto , Sociedades Médicas , Procedimientos Innecesarios , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Encuestas y Cuestionarios , Adulto Joven
6.
Chemotherapy ; 51 Suppl 1: 90-5, 2005.
Artículo en Inglés | MEDLINE | ID: mdl-15855752

RESUMEN

Hepatic encephalopathy (HE) is a neuropsychiatric syndrome, which develops in patients with acute or chronic liver failure. It is widely accepted to be due to impairment of hepatic clearance of toxic products from the gut such as ammonia. Accumulation of ammonia induces a glutamate neurotoxicity leading to an increased tone of the gamma-aminobutyric acid A (GABA-A) receptor system in the brain which results in HE. Factors either increasing the ammonia levels (protein load, constipation, sepsis, or gastrointestinal bleeding) or potentiating the functional activity of the GABAergic system [natural benzodiazepine-like compounds (NBZDs) or exogenous benzodiazepines] may act as precipitating factors of HE. NBZDs are present in trace amounts in the blood of normal subjects and have been found to be increased in the blood of patients with liver cirrhosis, with or without HE. These compounds may derive either from the diet since they have been found in plants, vegetables and animals or from gut bacteria. The observation that intestinal bacterial flora is involved in the production of both primary agent of HE (ammonia) and precipitating factors (NBZDs) suggests that the use of nonabsorbable antibiotics such as rifaximin may be useful in preventing episodes of HE in patients with liver cirrhosis.


Asunto(s)
Antibacterianos/uso terapéutico , Encefalopatía Hepática/prevención & control , Rifamicinas/uso terapéutico , Amoníaco/metabolismo , Animales , Antibacterianos/farmacocinética , Antidepresivos/efectos adversos , Antidepresivos/sangre , Bacterias/metabolismo , Benzodiazepinas/efectos adversos , Benzodiazepinas/sangre , Ensayos Clínicos como Asunto , Humanos , Absorción Intestinal , Intestinos/microbiología , Rifamicinas/farmacocinética , Rifaximina
7.
Biochem Biophys Res Commun ; 313(1): 62-6, 2004 Jan 02.
Artículo en Inglés | MEDLINE | ID: mdl-14672698

RESUMEN

The peripheral benzodiazepine receptor (PBR), an internal protein of the mammalian mitochondrial membrane, is involved in several metabolic functions such as steroidogenesis, oxidative phosphorylation, and regulation of cell proliferation. Here we report the presence of PBRs in parenchymal and meristematic tissues of potato (Solanum tuberosum). PBRs are heterogeneously distributed in potato and are highly expressed in meristematic cells. In particular the receptor protein is mainly localised in the meristematic nuclear subcellular preparation. This 30-36 kDa protein, which corresponds to PBR, is increased, indeed, in meristematic compared to the parenchymal tissue. This suggests an involvement of this receptor in the regulation of cell plant growth. In addition, the demonstration that PBRs are also present in vegetables supports the hypothesis of a highly conserved receptor system during phylogenesis.


Asunto(s)
Receptores de GABA-A/metabolismo , Solanum tuberosum/metabolismo , Benzodiazepinonas/química , Benzodiazepinonas/metabolismo , Membrana Celular/metabolismo , Concentración de Iones de Hidrógeno , Inmunohistoquímica , Meristema/citología , Meristema/metabolismo , Ensayo de Unión Radioligante , Receptores de GABA-A/aislamiento & purificación , Solanum tuberosum/citología , Solanum tuberosum/ultraestructura , Fracciones Subcelulares/metabolismo , Temperatura , Distribución Tisular , Tritio
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA